Status:
COMPLETED
Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
DPYD Gene Mutation
Gastrointestinal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
5-fluorouracil and capecitabine, sometimes called 5-FU, fluoropyrimidines, or Xeloda are a type of chemotherapy. Many people have side effects from these drugs like nausea, diarrhea, or blood problems...
Detailed Description
INTRODUCTION AND PURPOSE: Fluoropyrimidines (FPs) are the cornerstone of treatment for several gastrointestinal (GI) malignancies. Approximately 5-7% of patients carry reduced function variants in DP...
Eligibility Criteria
Inclusion
- Fluent in English
- Currently involved in the practice or policy of GI oncology/DPYD testing/FP use/Healthcare Development OR
- Prescribed a FP for GI cancer diagnosis in the past six months AND Currently licensed to provide health care in Pennsylvania or New Jersey OR
- Previous diagnosis of GI malignancy or family member who had GI malignancy
Exclusion
- Less than 18 years old
Key Trial Info
Start Date :
September 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06559462
Start Date
September 19 2024
End Date
August 28 2025
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104